AstraZeneca PLC vs General Motors Company: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and General Motors Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating General Motors Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and General Motors Company is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against $185.0B for General Motors Company, while their respective market capitalizations stand at $254.6B and $74.9B. AstraZeneca PLC is headquartered in United Kingdom and General Motors Company in United States, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

General Motors Company: General Motors (NYSE: GM) is the largest U.S. automaker by sales, with 2.85 million U.S. deliveries and about a 17% market share in 2025. Based in Detroit, it sells vehicles under Chevrolet, GMC, Cadillac, and Buick, and runs GM Financial for auto loans and leases. Its identity today is tied to profitable pickups such as the Silverado and Sierra and large SUVs such as the Escalade, which fund a slower-than-planned move into EVs, software, and driver assistance.

AstraZeneca PLC and General Motors Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and General Motors Company.

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

General Motors Company business model: GM makes money mainly by building and wholesaling vehicles to its dealer network, then earning a second layer of profit through GM Financial, its captive lender. GM North America (GMNA) is the profit engine: full-size pickups such as the Chevrolet Silverado and GMC Sierra and large SUVs such as the Tahoe, Suburban, Yukon, and Cadillac Escalade carry far higher margins than small cars or current EVs. GM International covers markets such as South America, South Korea, and the Middle East, while China is run through joint ventures (notably SAIC-GM) whose results show up as equity income rather than consolidated revenue. GM Financial earns interest and lease income from retail loans, leases, and dealer floorplan lines that also help move GM inventory. A smaller but growing layer of recurring revenue comes from software and services such as OnStar and the Super Cruise hands-free driving system. GM sold Opel/Vauxhall to PSA in 2017 and stopped selling vehicles in India the same year, so its footprint is now concentrated on North America.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of General Motors Company.

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

General Motors Company competitive advantage: GM's clearest advantage is scale in U.S. full-size pickups and SUVs: it has led the full-size pickup segment for six straight years, selling about 940,000 in 2025. That franchise, a national Chevrolet, GMC, Buick, and Cadillac dealer network, and GM Financial's captive lending give it cash flow and pricing power that newer EV-only rivals do not have. Super Cruise and OnStar give it a software and services base that competitors are still building.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and General Motors Company each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

General Motors Company growth strategy: GM's growth strategy has shifted from an all-EV push to flexibility. It still sells EVs on its Ultium-based platforms, such as the Chevrolet Equinox EV and Cadillac Lyriq, but after 2025 it cut EV capacity, kept investing in gas trucks and SUVs, and plans lower-cost lithium manganese-rich (LMR) cells with LG Energy Solution. In December 2024 GM stopped funding the Cruise robotaxi business and folded that work into its own engineering team. Growth now rests on software and services (OnStar, Super Cruise, and a planned eyes-off driving system), plus disciplined pricing and inventory.

A closer look at the financial trajectory of AstraZeneca PLC and General Motors Company rounds out the comparison.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.

General Motors Company: GM's finances are funded by internal-combustion trucks and SUVs. In 2025 it generated $185.0 billion of revenue, $12.7 billion of EBIT-adjusted, and $10.6 billion of adjusted automotive free cash flow, but EV write-downs cut net income attributable to stockholders 55% to $2.7 billion. Q1 2026 revenue was $43.6 billion with $2.6 billion of net income; Q2 2026 revenue was $48.0 billion with $1.3 billion of net income, $3.9 billion of EBIT-adjusted, and North America margins back inside GM's 8-10% target. GM returns large amounts of cash to shareholders and approved a new $6.0 billion buyback alongside a 20% higher quarterly dividend in January 2026.